Men with Certain Pathogenic Variants Had a Higher Incidence of Prostate Cancer
|
By LabMedica International staff writers Posted on 17 Nov 2021 |
|
Image: Men with Certain Pathogenic Variants Had a Higher Incidence of Prostate Cancer (Photo courtesy of UrologyAustin)
Prostate cancer is one of the major causes of morbidity and mortality in men worldwide. The importance of germline genetic variation for identifying men at increased risk of prostate cancer to enable targeted screening and early detection has become increasingly recognized.
Lynch syndrome is a rare familial cancer syndrome caused by pathogenic variants in the mismatch repair genes MLH1, MSH2, MSH6, or PMS2, that cause predisposition to various cancers, predominantly colorectal and endometrial cancer. Data are emerging that pathogenic variants in mismatch repair genes increase the risk of early-onset aggressive prostate cancer.
An a large team of international scientists led by the Institute of Cancer Research (London, UK) recruited between Sept 28, 2012, and March 1, 2020, 828 men (644 carriers of mismatch repair pathogenic variants [204 carriers of MLH1, 305 carriers of MSH2, and 135 carriers of MSH6] and 184 non-carrier controls [65 non-carriers of MLH1, 76 non-carriers of MSH2, and 43 non-carriers of MSH6]), and in order to boost the sample size for the non-carrier control groups, they randomly selected 134 non-carriers from the BRCA1 and BRCA2 cohort of the IMPACT study, who were included in all three non-carrier cohorts.
The overall positive predictive value of biopsy using a PSA threshold of 3.0 ng/mL was 51.4%. A concurrent serum sample was taken for PSA quality assurance testing for analysis using the ProStatus PSA Free/Total DELFIA assay (PerkinElmer Life and Analytical Sciences, Boston, MA, USA). The selected mismatch repair genes were sequenced from germline DNA using targeted next-generation sequencing and analyzed for pathogenic variants using Agilent SureCall (Agilent Technologies, Santa Clara, CA, USA).
The investigators reported that of 962 men, 6% had PSA readings above 3.0 ng/mL, and 4% elected to have a biopsy. Of the 35 biopsies performed, 18 (1.9% of the entire cohort) indicated the presence of cancer. For the incidence of clinically significant prostate cancer, the rate among MSH2 carriers was 3.6% (95% CI 1.8-6.4) and 2.2% among MSH6 carriers (95% CI 0.5-6.4) compared with 0% in both non-carrier control groups. Prostate cancer incidence, using a PSA threshold of higher than 3.0 ng/mL, was higher in MSH2 carriers than in MSH2 non-carrier controls (4.3% versus 0.5%) and MSH6 carriers than MSH6 non-carrier controls (3.0% versus 0%).
The authors concluded that results from the study bolster consideration of targeted PSA screening for prostate cancer in men with MSH2 and MSH6 pathogenic variants to increase the detection of prostate tumors that are highly likely to need treatment based on national and international guidelines. The study was published on November 1, 2021 in the journal The Lancet Oncology.
Related Links:
Institute of Cancer Research
PerkinElmer Life and Analytical Sciences
Agilent Technologies
Lynch syndrome is a rare familial cancer syndrome caused by pathogenic variants in the mismatch repair genes MLH1, MSH2, MSH6, or PMS2, that cause predisposition to various cancers, predominantly colorectal and endometrial cancer. Data are emerging that pathogenic variants in mismatch repair genes increase the risk of early-onset aggressive prostate cancer.
An a large team of international scientists led by the Institute of Cancer Research (London, UK) recruited between Sept 28, 2012, and March 1, 2020, 828 men (644 carriers of mismatch repair pathogenic variants [204 carriers of MLH1, 305 carriers of MSH2, and 135 carriers of MSH6] and 184 non-carrier controls [65 non-carriers of MLH1, 76 non-carriers of MSH2, and 43 non-carriers of MSH6]), and in order to boost the sample size for the non-carrier control groups, they randomly selected 134 non-carriers from the BRCA1 and BRCA2 cohort of the IMPACT study, who were included in all three non-carrier cohorts.
The overall positive predictive value of biopsy using a PSA threshold of 3.0 ng/mL was 51.4%. A concurrent serum sample was taken for PSA quality assurance testing for analysis using the ProStatus PSA Free/Total DELFIA assay (PerkinElmer Life and Analytical Sciences, Boston, MA, USA). The selected mismatch repair genes were sequenced from germline DNA using targeted next-generation sequencing and analyzed for pathogenic variants using Agilent SureCall (Agilent Technologies, Santa Clara, CA, USA).
The investigators reported that of 962 men, 6% had PSA readings above 3.0 ng/mL, and 4% elected to have a biopsy. Of the 35 biopsies performed, 18 (1.9% of the entire cohort) indicated the presence of cancer. For the incidence of clinically significant prostate cancer, the rate among MSH2 carriers was 3.6% (95% CI 1.8-6.4) and 2.2% among MSH6 carriers (95% CI 0.5-6.4) compared with 0% in both non-carrier control groups. Prostate cancer incidence, using a PSA threshold of higher than 3.0 ng/mL, was higher in MSH2 carriers than in MSH2 non-carrier controls (4.3% versus 0.5%) and MSH6 carriers than MSH6 non-carrier controls (3.0% versus 0%).
The authors concluded that results from the study bolster consideration of targeted PSA screening for prostate cancer in men with MSH2 and MSH6 pathogenic variants to increase the detection of prostate tumors that are highly likely to need treatment based on national and international guidelines. The study was published on November 1, 2021 in the journal The Lancet Oncology.
Related Links:
Institute of Cancer Research
PerkinElmer Life and Analytical Sciences
Agilent Technologies
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
HIV-1 Test
HIV-1 Real Time RT-PCR Kit
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
Latest Pathology News
- Spit Test More Accurate at Identifying Future Prostate Cancer Risk
- DNA Nanotechnology Boosts Sensitivity of Test Strips
- Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
- New Error-Corrected Method to Help Detect Cancer from Blood Samples Alone
- "Metal Detector" Algorithm Hunts Down Vulnerable Tumors
- Novel Technique Uses ‘Sugar’ Signatures to Identify and Classify Pancreatic Cancer Cell Subtypes
- Advanced Imaging Reveals Mechanisms Causing Autoimmune Disease
- AI Model Effectively Predicts Patient Outcomes in Common Lung Cancer Type
- AI Model Predicts Patient Response to Bladder Cancer Treatment
- New Laser-Based Method to Accelerate Cancer Diagnosis
- New AI Model Predicts Gene Variants’ Effects on Specific Diseases
- Powerful AI Tool Diagnoses Coeliac Disease from Biopsy Images with Over 97% Accuracy
- Pre-Analytical Conditions Influence Cell-Free MicroRNA Stability in Blood Plasma Samples
- 3D Cell Culture System Could Revolutionize Cancer Diagnostics
- Painless Technique Measures Glucose Concentrations in Solution and Tissue Via Sound Waves
- Skin-Based Test to Improve Diagnosis of Rare, Debilitating Neurodegenerative Disease
Channels
Clinical Chemistry
view channel
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read more
Hematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read more
Immunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read more
Microbiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Pathology
view channel
Spit Test More Accurate at Identifying Future Prostate Cancer Risk
Currently, blood tests that measure the level of a protein called prostate-specific antigen (PSA) are commonly used to identify men at higher risk for prostate cancer. This test is typically used based... Read more
DNA Nanotechnology Boosts Sensitivity of Test Strips
Since the Covid-19 pandemic, most people have become familiar with paper-based rapid test strips, also known as lateral flow immunoassays (LFIAs). These tests are used to quickly detect biomarkers that... Read more
Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more
Technology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read more
Industry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more
